Details of the Researcher

PHOTO

Saori Katayama
Section
Tohoku University Hospital
Job title
Assistant Professor
Degree
e-Rad No.
50812278

Research Interests 3

  • 先天性血小板減少症

  • 血液腫瘍

  • 小児がん

Research Areas 2

  • Life sciences / Fetal medicine/Pediatrics /

  • Life sciences / Hematology and oncology /

Awards 2

  1. 第8回日本小児血液・がん学会学術賞

    2018/11　一般社団法人 日本小児血液・がん学会　GATA2 haploinsufficieny accelerates EVI1-driven leukemogenesis

  2. 第89回日本生化学会大会若手優秀発表賞

    2016/09　公益社団法人 日本生化学会　GATA2遺伝子ヘテロ欠失は３番染色体逆位を伴う白血病の発症を促進する

Papers 49

  1. Comprehensive genetic analysis for identification of monogenic disorders and selection of appropriate treatments in pediatric patients with persistent thrombocytopenia. International-journal

    Daichi Sato, Hinako Kirikae, Tomohiro Nakano, Saori Katayama, Hisao Yaoita, Jun Takayama, Gen Tamiya, Shigeo Kure, Atsuo Kikuchi, Yoji Sasahara

    Pediatric hematology and oncology　41　(8)　541-556　2024/11

    DOI： 10.1080/08880018.2024.2395358 　

    More details Close

    Persistent thrombocytopenia is caused by various diseases, including immune thrombocytopenia, inherited thrombocytopenia, and inherited bone marrow failure syndromes. Considering the large number of genes responsible for inherited disorders, comprehensive genetic analysis is required to diagnose monogenic disorders. In this study, we enrolled 53 pediatric patients with persistent thrombocytopenia exhibiting visually small or normal-sized platelets. We performed whole-exome sequencing, including 56 genes responsible for inherited thrombocytopenia, and evaluated clinical parameters according to disease type. Among 53 patients, 12 patients (22.6%) were diagnosed with monogenic disorders. Nine patients had a family history of thrombocytopenia. Pathogenic or novel variants of genes responsible for inherited thrombocytopenia were identified in three and six patients, respectively. The variants in genes for inherited thrombocytopenia with large or giant platelets were unexpectedly identified in six patients. Pathogenic variants in genes for inherited bone marrow failure syndromes with systemic features were identified in three patients with atypical symptoms. Since the definitive diagnostic methods for immune thrombocytopenia are limited, and a substantial number of patients with inherited thrombocytopenia are at a high risk of developing malignancies, comprehensive genetic analysis is indispensable for selecting appropriate therapies, avoidance of unnecessary treatments for immune thrombocytopenia, and long-term follow-up of patients with inherited thrombocytopenia.

  2. Efficacy of rituximab for the treatment and prevention of autoimmunity in patients with Wiskott-Aldrich syndrome and X-linked thrombocytopenia

    Saori Katayama, Tomohiro Nakano, Tasuku Suzuki, Masahiro Irie, Hidetaka Niizuma, Atsuo Kikuchi, Yoji Sasahara

    Clinical Immunology Communications　5　34-40　2024/06

    Publisher: Elsevier BV

    DOI： 10.1016/j.clicom.2024.04.002 　

    ISSN： 2772-6134

  3. 治療後遠隔期に中枢神経外多発骨・骨髄転移再発を来した髄芽腫の一例

    戒能 明, 入江 正寛, 岩淵 蒼太, 中野 智太, 鈴木 資, 片山 紗乙莉, 新妻 秀剛, 下田 由輝, 金森 政之, 遠藤 英徳, 笹原 洋二, 菊池 敦生

    日本小児血液・がん学会雑誌　61　(1)　109-109　2024/05

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  4. 治療後遠隔期に中枢神経外多発骨・骨髄転移再発を来した髄芽腫の一例

    戒能 明, 入江 正寛, 岩淵 蒼太, 中野 智太, 鈴木 資, 片山 紗乙莉, 新妻 秀剛, 下田 由輝, 金森 政之, 遠藤 英徳, 笹原 洋二, 菊池 敦生

    日本小児血液・がん学会雑誌　61　(1)　109-109　2024/05

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  5. 持続性血小板減少症の小児患者における単一遺伝子疾患を同定するための包括的遺伝子解析

    佐藤 大地, 切替 日奈子, 中野 智太, 片山 紗乙莉, 矢尾板 久雄, 呉 繁夫, 菊池 敦生, 笹原 洋二

    日本小児科学会雑誌　128　(2)　267-267　2024/02

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  6. 神経芽腫再発に対する臍帯血移植後に発症したFSGS

    長谷山 知奈未, 内田 奈生, 田山 耕太郎, 片山 紗乙莉, 入江 正寛, 菊池 敦生

    日本小児科学会雑誌　128　(2)　327-327　2024/02

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  7. 肝芽腫を発症した21モノソミーモザイクの女児

    庄司 理以沙, 片山 紗乙莉, 諸田 真莉子, 中野 智太, 鈴木 資, 入江 正寛, 新妻 秀剛, 笹原 洋二, 菊池 敦生

    日本小児血液・がん学会雑誌　60　(2)　167-168　2023/08

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  8. Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor. International-journal

    Akira Kaino, Hidetaka Niizuma, Saori Katayama, Masahiro Irie, Tomohiro Nakano, Daichi Sato, Tsuyoshi Saito, Shunsuke Kato, Yoshiyuki Suehara, Yoji Sasahara, Atsuo Kikuchi

    Pediatric blood & cancer　70　(8)　e30330　2023/08

    DOI： 10.1002/pbc.30330 　

  9. Outcomes following induction failure in Japanese children with acute lymphoblastic leukemia.

    Chihaya Imai, Atsushi Sato, Mitsuteru Hiwatari, Yasuto Shimomura, Toshinori Hori, Souichi Suenobu, Toshihiko Imamura, Junichi Hara, Daisuke Hasegawa, Hiroyuki Takahashi, Kunihiko Moriya, Saori Katayama, Daisuke Tomizawa, Hiroshi Moritake, Takashi Taga, Keizo Horibe, Katsuyoshi Koh, Atsushi Manabe, Yasuhiro Okamoto

    International journal of hematology　118　(1)　99-106　2023/04/10

    DOI： 10.1007/s12185-023-03600-3 　

    More details Close

    The characteristics and prognosis of Japanese children with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission after remission induction chemotherapy (i.e., experience induction failure) are poorly understood. Therefore, we retrospectively analyzed data of patients enrolled in Japanese clinical trials for newly diagnosed ALL between 1996 and 2009. Among 4956 participants, 89 (1.8%) experienced induction failure. With a 6.0-year median follow-up, the 5-year overall survival rate of the entire cohort was 43.0% ± 5.5%. Survival rates did not differ between patients with B-cell precursor ALL (BCP-ALL) and T-cell ALL (T-ALL). In multivariate analysis, day 15 M3 marrow (bone marrow blast count ≥ 25%) was significantly correlated with poorer survival in the whole or BCP-ALL cohorts. In T-ALL, age < 6 years was significantly associated with poor survival. However, due to the small sample size, this correlation must be further investigated. Most T-ALL and BCR-ABL-positive BCP-ALL patients underwent allogeneic stem cell transplantation (allo-SCT). Survival rates did not differ between BCR-ABL-negative BCP-ALL patients who did and did not undergo allo-SCT, possibly due to the inclusion of lower-risk patients in the latter group. In conclusion, the induction failure rate and survival after diagnosis of induction failure in our study were comparable to previously reported figures.

  10. Reduced-intensity conditioning is effective for allogeneic hematopoietic stem cell transplantation in infants with MECOM-associated syndrome.

    Masahiro Irie, Tetsuya Niihori, Tomohiro Nakano, Tasuku Suzuki, Saori Katayama, Kunihiko Moriya, Hidetaka Niizuma, Nobu Suzuki, Yuka Saito-Nanjo, Masaei Onuma, Takeshi Rikiishi, Atsushi Sato, Mayumi Hangai, Mitsuteru Hiwatari, Junji Ikeda, Reo Tanoshima, Norio Shiba, Yuki Yuza, Nobuyuki Yamamoto, Yoshiko Hashii, Motohiro Kato, Junko Takita, Miho Maeda, Yoko Aoki, Masue Imaizumi, Yoji Sasahara

    International journal of hematology　117　(4)　598-606　2022/12/14

    DOI： 10.1007/s12185-022-03505-7 　

    More details Close

    Mutations in the MECOM encoding EVI1 are observed in infants who have radioulnar synostosis with amegakaryocytic thrombocytopenia. MECOM-associated syndrome was proposed based on clinical heterogeneity. Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for progressive bone marrow failure. However, data regarding allogeneic HSCT for this rare disease are limited. We retrospectively assessed overall survival, conditioning regimen, regimen-related toxicities and long-term sequelae in six patients treated with allogeneic HSCT. All patients received a reduced-intensity conditioning (RIC) regimen consisting of fludarabine, cyclophosphamide or melphalan, and rabbit anti-thymocyte globulin and/or low-dose total body/thoracic-abdominal/total lymphoid irradiation, followed by allogeneic bone marrow or cord blood transplantation from unrelated donors between 4 and 18 months of age. All patients survived and achieved stable engraftment and complete chimerization with the donor type. Moreover, no patient experienced severe regimen-related toxicities, and only lower grades of acute graft-versus-host disease were observed. Three patients treated with low-dose irradiation had relatively short stature compared to three patients not treated with irradiation. Therefore, allogeneic HSCT with RIC is an effective and feasible treatment for infants with MECOM-associated syndrome. Future studies are needed to evaluate the use of low-dose irradiation to avoid risks of other long-term sequelae.

  11. Type II pleuropulmonary blastoma with DICER1 mutation

    Taichi Fukuzawa, Yuki Endo, Masahiro Irie, Hideyuki Sasaki, Hironori Kudo, Megumi Nakamura, Ryo Ando, Ryuji Okubo, Tsuyoshi Sakurai, Masatoshi Hashimoto, Keisuke Tada, Yudai Nakajima, Kosuke Sato, Ryoma Endo, Hidekazu Aoki, Saori Katayama, Tomohiro Nakano, Motoshi Wada

    Journal of Pediatric Surgery Case Reports　87　102468-102468　2022/12

    Publisher: Elsevier BV

    DOI： 10.1016/j.epsc.2022.102468 　

    ISSN： 2213-5766

  12. Comprehensive genomic profiling suggested multifocal development of retinoblastoma in a single eye. International-journal

    Miyu Sai, Hidetaka Niizuma, Kohei Yagi, Tomohiro Nakano, Saori Katayama, Noriko Himori, Masahiro Irie, Yoji Sasahara

    Pediatric blood & cancer　e30031　2022/10/02

    DOI： 10.1002/pbc.30031 　

  13. 小児科と緩和ケアチームの協力体制 症例と当院の活動から(How palliative care team support us pediatricians: Case reports and cooperative works from Tohoku)

    Kaino Akira, Tagami Keita, Sato Mamiko, Katayama Saori, Suzuki Tasuku, Moriya Kunihiko, Irie Masahiro, Niizuma Hidetaka, Inoue Akira, Sasahara Yoji

    日本小児血液・がん学会雑誌　59　(4)　246-246　2022/10

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  14. Stage M Infantile Neuroblastoma With Involvement of Falx Cerebri: Case Report and Literature Review. International-journal

    Miyu Sai, Kunihiko Moriya, Akira Kaino, Tasuku Suzuki, Saori Katayama, Hidekazu Aoki, Yoji Sasahara

    Journal of pediatric hematology/oncology　2022/09/19

    DOI： 10.1097/MPH.0000000000002548 　

    More details Close

    Neuroblastoma is the most common extracranial solid tumor in children. When metastasis to the falx cerebri is present, it is classified as stage M; however, its behavior has not been well characterized. Here we present a case of stage M infantile neuroblastoma (NB) with involvement of the falx cerebri, and also summarize the clinical profiles of previously reported cases. Notably, all of the tumors resolved with low-dose chemotherapy alone. Although further study is needed to distinguish NBs presenting at these different intracranial locations, NB with metastasis to the falx cerebri may be categorized as MS when diagnosed at less than 18 months of age.

  15. 術前化学療法を施行した両側性Wilms腫瘍の2例

    中村 春彦, 入江 正寛, 片山 紗乙莉, 森谷 邦彦, 力石 健, 新妻 秀剛, 笹原 洋二, 呉 繁夫

    日本小児血液・がん学会雑誌　59　(2)　202-203　2022/07

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  16. 腫瘍検体でDICER1変異を同定した胸膜肺芽腫の一例

    中野 智太, 鈴木 資, 片山 紗乙莉, 入江 正寛, 福澤 太一, 新妻 秀剛, 笹原 洋二

    日本小児血液・がん学会雑誌　59　(2)　204-204　2022/07

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  17. Intraoperative Placement of an Absorbable Spacer Prior to Radiation Therapy for a Malignant Peripheral Nerve Sheath Tumor

    Yuki Endo, Taichi Fukuzawa, Masahiro Irie, Hideyuki Sasaki, Hironori Kudo, Ryo Ando, Ryuji Okubo, Saori Katayama, Masatoshi Hashimoto, Kosuke Sato, Masahito Tachibana, Hidekazu Aoki, Masayuki Araya, Koichi Hirabayashi, Shoji Saito, Hidekazu Masaki, Yozo Nakazawa, Yoji Sasahara, Motoshi Wada

    Case Reports in Oncology　2022/05/20

    DOI： 10.1159/000524824 　

  18. The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Münster (BFM)95-based protocol. International-journal

    Kunihiko Moriya, Toshihiko Imamura, Saori Katayama, Akira Kaino, Kenji Okamoto, Norihumi Yokoyama, Suguru Uemura, Hironobu Kitazawa, Masahiro Sekimizu, Hidefumi Hiramatsu, Ikuya Usami, Hisashi Ishida, Daiichiro Hasegawa, Asahito Hama, Akiko Moriya-Saito, Atsushi Sato, Yoji Sasahara, Souichi Suenobu, Keizo Horibe, Junichi Hara

    British journal of haematology　196　(5)　1257-1261　2022/03

    DOI： 10.1111/bjh.17988 　

    More details Close

    In this study, we performed a retrospective analysis of a cohort of Japanese paediatric patients with B-cell precursor (BCP)-acute lymphoblastic leukaemia (ALL) treated with a Berlin-Frankfurt-Münster (BFM)95-based protocol, to clarify the incidence, clinical characteristics, and risk factors of osteonecrosis (ON) in comparison to the ALL-02 protocol. We identified a high frequency of ON with the BFM95-based protocol compared to the ALL-02 protocol. The incidence of symptomatic ON with the BFM95-based protocol is comparable to previous studies in Western countries. We believe that the type of treatment regimen has more impact on the incidence of symptomatic ON in paediatric ALL than ethnicity.

  19. Tリンパ芽球性リンパ腫治療中にステロイドミオパチーを併発した1例

    中村 春彦, 森谷 邦彦, 片山 紗乙莉, 入江 正寛, 力石 健, 新妻 秀剛, 笹原 洋二, 呉 繁夫

    日本小児科学会雑誌　125　(11)　1606-1606　2021/11

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  20. Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis. International-journal

    Masahiro Irie, Tomohiro Nakano, Saori Katayama, Tasuku Suzuki, Kunihiko Moriya, Yuko Watanabe, Nobu Suzuki, Yuka Saitoh-Nanjyo, Masaei Onuma, Takeshi Rikiishi, Hidetaka Niizuma, Yoji Sasahara, Shigeo Kure

    Cancer reports (Hoboken, N.J.)　5　(8)　e1579　2021/11/01

    DOI： 10.1002/cnr2.1579 　

    More details Close

    BACKGROUND: Better therapeutic options other than conventional chemotherapy for pediatric patients with refractory Langerhans cell histiocytosis (LCH) remain undetermined. CASE: We successfully treated two patients with refractory and risk organ negative LCH with clofarabine (CLO) monotherapy after recurrence. We administered total 23 courses of CLO monotherapy in patient 1 and 4 courses in patient 2. Both patients had distinct clinical manifestations but achieved a durable complete response with acceptable adverse effects of transient myelosuppression. CLO monotherapy was still effective when he had the second recurrent lesion after first completion of CLO in patient 1. We could discontinue prednisolone to control his refractory inflammation of LCH after completing CLO chemotherapy in patient 2. CONCLUSION: Although large-scale studies are warranted, CLO monotherapy could be a therapeutic option for high efficacy and feasibility besides other intensive combination chemotherapies or allogeneic hematopoietic stem cell transplantation for refractory LCH without risk organ involvement in children.

  21. びまん性大細胞型B細胞性リンパ腫を合併し、治療に難渋した毛細血管拡張性運動失調症の一例(Ataxia-telangiectasia with refractory diffuse large B cell lymphoma caused by novel compound heterozygous ATM variants)

    Sato Daichi, Moriya Kunihiko, Nakano Tomohiro, Katayama Saori, Niizuma Hidetaka, Sasahara Yoji, Kure Shigeo

    日本小児血液・がん学会雑誌　58　(4)　199-199　2021/10

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  22. 新規TSC2遺伝子変異とTP53の体細胞性変異により骨肉腫を発症した1例(A pediatric case of osteosarcoma and tuberous sclerosis complex with a somatic mutation in the TP53 gene)

    Moriya Kunihiko, Sato Daichi, Nakano Tomohiro, Watanuki Munenori, Katayama Saori, Niizuma Hidetaka, Sasahara Yoji, Kure Shigeo

    日本小児血液・がん学会雑誌　58　(4)　233-233　2021/10

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  23. 同種骨髄移植後、肝類洞閉塞症候群とITPが合併した骨髄異形成症候群の8歳女児例(A case report of 8 year-old girl with MDS, suffering from SOS after allogeneic BMT, followed by post-transplantation thrombocytopenia)

    Irie Masahiro, Sasahara Yoji, Nakano Tomohiro, Suzuki Tasuku, Katayama Saori, Moriya Kunihiko, Niizuma Hidetaka, Rikiishi Takeshi, Hirayama Masashi, Kure Shigeo

    日本小児血液・がん学会雑誌　58　(4)　247-247　2021/10

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  24. LRBA遺伝子の新規複合ヘテロ変異を伴い、乳児期に発症した劇症1型糖尿病の1例(Infantile-onset fulminant type 1 diabetes mellitus caused by novel compound heterozygous LRBA variants)

    Kaino Akira, Moriya Kunihiko, Nakano Tomohiro, Sato Daichi, Katayama Saori, Niizuma Hidetaka, Sasahara Yoji, Kure Shigeo

    日本小児血液・がん学会雑誌　58　(4)　260-260　2021/10

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  25. 単施設における網膜芽細胞腫の後方視的検討(Age at diagnosis and prognosis of retinoblastoma: a retrospective single center observational study)

    Sai Miyu, Niizuma Hidetaka, Irie Masahiro, Moriya Kunihiko, Katayama Saori, Suzuki Tasuku, Sasahara Yoji, Kure Shigeo

    日本小児血液・がん学会雑誌　58　(4)　263-263　2021/10

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  26. Refractory T-cell/histiocyte-rich large B-cell lymphoma in a patient with ataxia-telangiectasia caused by novel compound heterozygous variants in ATM.

    Daichi Sato, Kunihiko Moriya, Tomohiro Nakano, Chihiro Miyagawa, Saori Katayama, Hidetaka Niizuma, Yoji Sasahara, Shigeo Kure

    International journal of hematology　114　(6)　735-741　2021/08/23

    DOI： 10.1007/s12185-021-03203-w 　

    More details Close

    Ataxia-telangiectasia (A-T) is an autosomal recessive chromosomal breakage syndrome caused by mutation of the ATM (A-T mutated) gene, which encodes a protein kinase that has a major role in the cellular response to DNA damage. Approximately, 10% of A-T patients develop lymphoid malignancies. Deaths caused by extreme sensitivity to chemotherapy for malignancy have been reported, and cancer treatment in A-T is extraordinarily difficult, needing careful monitoring and individualized protocols. We report the case of a 12-year-old girl with A-T diagnosed at the age of 3 in association with IgA deficiency and recurrent pulmonary infections. Sanger sequencing revealed compound heterozygosity of the ATM gene, which bore two novel mutations. At the age of 12, she developed stage IV T-cell/histiocyte-rich large B-cell lymphoma. The tumor was resistant to chemotherapy, and she unfortunately died of cardiac insufficiency and multiple organ failure induced by rapid progression of the disease. The treatment approach for children with A-T and advanced-stage B-non-Hodgkin lymphoma must be refined.

  27. A pediatric case of osteosarcoma and tuberous sclerosis complex with a novel germline mutation in the TSC2 gene and a somatic mutation in the TP53 gene. International-journal

    Kaoru Kuroda, Kunihiko Moriya, Tomohiro Nakano, Ryoko Saito, Daichi Sato, Saori Katayama, Hidetaka Niizuma, Munenori Watanuki, Mitsugu Uematsu, Yoji Sasahara, Shigeo Kure

    Pediatric blood & cancer　68　(6)　e28960　2021/06

    DOI： 10.1002/pbc.28960 　

  28. Case Report: Infantile-Onset Fulminant Type 1 Diabetes Mellitus Caused by Novel Compound Heterozygous LRBA Variants. International-journal

    Eriko Totsune, Tomohiro Nakano, Kunihiko Moriya, Daichi Sato, Dai Suzuki, Akinobu Miura, Saori Katayama, Hidetaka Niizuma, Junko Kanno, Menno C van Zelm, Kohsuke Imai, Hirokazu Kanegane, Yoji Sasahara, Shigeo Kure

    Frontiers in immunology　12　677572-677572　2021

    DOI： 10.3389/fimmu.2021.677572 　

    More details Close

    Lipopolysaccharide-responsive beige-like anchor (LRBA) deficiency is a subtype of common variable immune deficiency (CVID). Numerous case reports and cohort studies have described a broad spectrum of clinical manifestations and variable disease phenotypes, including immune dysregulation, enteropathy, and recurrent infections. Although LRBA deficiency is an autosomal recessive primary immunodeficiency resulting in a phenotype similar to CVID, it is a monogenic disease and separate from CVID. Recently, in a report of monogenic primary immunodeficiency disorder associated with CVID and autoimmunity, the most common mutated gene was LRBA. We report the case of a girl who presented with fulminant type 1 diabetes at age 7 months. She later experienced recurrent bacterial infections with neutropenia and idiopathic thrombocytopenic purpura. Clinical genome sequencing revealed compound heterozygosity of the LRBA gene, which bore two novel mutations. A genetic basis should be considered in the differential diagnosis for very young patients with fulminant autoimmunity, and the diagnostic work-up should include evaluation of markers of immunodeficiency.

  29. RNA-Seqにより原因遺伝子検索を行った骨髄増殖性腫瘍合併ETP-LBLの一例(Genetic analysis of an early T-cell precursor acute lymphoblastic lymphoma associated with myeloproliferative neoplasm)

    Katayama Saori, Nakano Tomohiro, Irie Masahiro, Moriya Kunihiko, Niizuma Hidetaka, Rikiishi Takeshi, Sasahara Yoji, Kure Shigeo

    日本小児血液・がん学会雑誌　57　(4)　226-226　2020/10

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  30. がん遺伝子パネル検査を施行した小児がん20例の検討 診断・治療に関する有用性(Clinical sequencing of 20 pediatric solid tumors: utility for molecular diagnosis and targeted therapy)

    Niizuma Hidetaka, Kaino Akira, Nakano Tomohiro, Katayama Saori, Moriya Kunihiko, Irie Masahiro, Rikiishi Takeshi, Sasahara Yoji, Kure Shigeo

    日本小児血液・がん学会雑誌　57　(4)　242-242　2020/10

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  31. がん遺伝子パネル検査でSMARCB1変異を認め、INI-1蛋白陽性のAT/RTと考えられた一例(Clinical sequencing revealed two distinct mutations in SMARCB1, in an INI-1 positive AT/RT)

    Kaino Akira, Niizuma Hidetaka, Moriya Kunihiko, Katayama Saori, Irie Masahiro, Rikiishi Takeshi, Saito Ryuta, Kanamori Masayuki, Sasahara Yoji, Kure Shigeo

    日本小児血液・がん学会雑誌　57　(4)　245-245　2020/10

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  32. Frantz腫瘍3例の経験と,脾摘に対する内科的対応について

    石川 孝太郎, 新妻 秀剛, 片山 紗乙莉, 森谷 邦彦, 入江 正寛, 力石 健, 福澤 太一, 笹原 洋二, 呉 繁夫

    日本小児科学会雑誌　124　(8)　1296-1296　2020/08

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  33. Frantz腫瘍3例の経験と,脾摘に対する内科的対応について

    石川 孝太郎, 新妻 秀剛, 片山 紗乙莉, 森谷 邦彦, 入江 正寛, 力石 健, 福澤 太一, 笹原 洋二, 呉 繁夫

    日本小児科学会雑誌　124　(8)　1296-1296　2020/08

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  34. Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation. Peer-reviewed

    Kunihiko Moriya, Tasuku Suzuki, Nao Uchida, Tomohiro Nakano, Saori Katayama, Masahiro Irie, Takeshi Rikiishi, Hidetaka Niizuma, Satoshi Okada, Kohsuke Imai, Yoji Sasahara, Shigeo Kure

    International journal of hematology　112　(2)　258-262　2020/08

    DOI： 10.1007/s12185-020-02860-7 　

    More details Close

    Signal transducer and activator of transcription 1 gain-of-function (STAT1 GOF) mutations are the most common cause of chronic mucocutaneous candidiasis (CMC). We report the effect of oral ruxolitinib, an inhibitor of Janus kinase (JAK) family tyrosine kinases, on the clinical and immune status of a 3-year-old male with steroid-dependent severe autoimmunity due to a STAT1 GOF T385M mutation. The patient's susceptibility to infection improved with antimicrobial prophylaxis and immunoglobulin replacement therapy, but he continued to exhibit severely disabling symptoms of autoimmunity. More than one-third of patients with STAT1 GOF mutations present with autoimmune manifestations, and this patient's mutation was reported to cause CMC with autoimmunity. We analyzed the interleukin (IL)-17A and IFN-γ levels and immunophenotype by flow cytometry before and during treatment with ruxolitinib. The peripheral IL-17A level did not increase, but the IFN-γ level decreased after 4 months of therapy. The STAT1 phosphorylation level decreased significantly upon stimulation of patient cells with IFN-γ. Clinically, cytomegalovirus reactivation occurred, but was controlled. No other adverse effect was noted. We report the potential of JAK1/2 inhibition with ruxolitinib for both CMC and steroid-dependent autoimmunity. However, long-term administration is necessary, as the effect is not sustained after treatment is discontinued.

  35. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis. International-journal Peer-reviewed

    Ayaka Yamaoka, Mikiko Suzuki, Saori Katayama, Daiki Orihara, James Douglas Engel, Masayuki Yamamoto

    Blood advances　4　(8)　1722-1736　2020/04/28

    DOI： 10.1182/bloodadvances.2019000978 　

    More details Close

    Chromosomal rearrangements between 3q21 and 3q26 elicit high-risk acute myeloid leukemia (AML), which is often associated with elevated platelet and megakaryocyte (Mk) numbers. The 3q rearrangements reposition a GATA2 enhancer near the EVI1 (or MECOM) locus, which results in both EVI1 overexpression and GATA2 haploinsufficiency. However, the mechanisms explaining how the misexpression of these 2 genes individually contribute to leukemogenesis are unknown. To clarify the characteristics of differentiation defects caused by EVI1 and GATA2 misexpression and to identify the cellular origin of leukemic cells, we generated a system to monitor both inv(3) allele-driven EVI1 and Gata2 expression in 3q-rearranged AML model mice. A cell population in which both EVI1 and Gata2 were highly induced appeared in the bone marrows before the onset of frank leukemia. This population had acquired serial colony-forming potential. Because hematopoietic stem/progenitor cells (HSPCs) and Mks were enriched in this peculiar population, we analyzed the independent EVI1 and GATA2 contributions to HSPC and Mk. We found that inv(3)-driven EVI1 promotes accumulation of Mk-biased and myeloid-biased progenitors, Mks, and platelets, and that Gata2 heterozygous deletion enhanced Mk-lineage skewing of EVI1-expressing progenitors. Notably, inv(3)-directed EVI1 expression and Gata2 haploinsufficient expression cooperatively provoke a leukemia characterized by abundant Mks and platelets. These hematological features of the mouse model phenocopy those observed in human 3q AML. On the basis of these results, we conclude that inv(3)-driven EVI1 expression in HSPCs and Mks collaborates with Gata2 haploinsufficiency to provoke Mk-lineage skewing and leukemogenesis with excessive platelets, thus mimicking an important feature of human AML.

  36. 髄芽腫の放射線療法中に合併した難治性ITPに対し,rituximabが奏功した一例

    戒能 明, 新妻 秀剛, 入江 正寛, 片山 紗乙莉, 森谷 邦彦, 力石 健, 齋藤 竜太, 金森 政之, 笹原 洋二, 呉 繁夫

    日本小児科学会雑誌　124　(2)　321-321　2020/02

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  37. Two effects of GATA2 enhancer repositioning by 3q chromosomal rearrangements. International-journal Peer-reviewed

    Mikiko Suzuki, Saori Katayama, Masayuki Yamamoto

    IUBMB life　72　(1)　159-169　2020/01

    DOI： 10.1002/iub.2191 　

    More details Close

    Chromosomal inversion and translocation between 3q21 and 3q26 [inv (3)(q21.3q26.2) and t(3;3)(q21.3;q26.2), respectively] give rise to acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), which have poor prognoses. The chromosomal rearrangements reposition a GATA2 distal hematopoietic enhancer from the original 3q21 locus to the EVI1 (also known as MECOM) locus on 3q26. Therefore, the GATA2 enhancer from one of two GATA2 alleles drives EVI1 gene expression in hematopoietic stem and progenitor cells, which promotes the accumulation of abnormal progenitors and induces leukemogenesis. On the other hand, one allele of the GATA2 gene loses its enhancer, which results in reduced GATA2 expression. The GATA2 gene encodes a transcription factor critical for the generation and maintenance of hematopoietic stem and progenitor cells. GATA2 haploinsufficiency has been known to cause immunodeficiency and myeloid leukemia. Notably, reduced GATA2 expression suppresses the differentiation but promotes the proliferation of EVI1-expressing leukemic cells, which accelerates EVI1-driven leukemogenesis. A series of studies have shown that the GATA2 enhancer repositioning caused by the chromosomal rearrangements between 3q21 and 3q26 provokes misexpression of both the EVI1 and GATA2 genes and that these two effects coordinately elicit high-risk leukemia.

  38. 集学的治療後に再発したCD30陽性縦隔原発大細胞性B細胞性リンパ腫に対してBrentuximab Vedotinが著効した一例(A report of a patient with CD30 positive PMLBL, relapsed after multimodality therapy, successfully treated with Brentuximab Vedotin monotherapy)

    Irie Masahiro, Watanabe Mika, Katayama Saori, Moriya Kunihiko, Watanabe Yuko, Niizuma Hidetaka, Rikiishi Takeshi, Sasahara Yoji, Kure Shigeo

    日本小児血液・がん学会雑誌　56　(4)　212-212　2019/10

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  39. がん遺伝子パネル検査により分子診断・標的治療に繋がったALK転座陽性の肝門部腫瘍の一乳児例(Clinical sequencing revealed the ALK-related fusion gene in an infantile soft tissue sarcoma, leading to molecular diagnosis and ALK-targeted therapy)

    Kaino Akira, Niizuma Hidetaka, Suehara Yoshiyuki, Katayama Saori, Kato Shunsuke, Saito Tsuyoshi, Hayashi Takuo, Moriya Kunihiko, Irie Masahiro, Rikiishi Takeshi, Sasahara Yoji, Kure Shigeo

    日本小児血液・がん学会雑誌　56　(4)　259-259　2019/10

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  40. GATA2ハプロ不全はEVI1誘導性白血病の発症を促進する

    片山 紗乙莉, 鈴木 未来子, 笹原 洋二, 呉 繁夫, 山本 雅之

    日本小児血液・がん学会雑誌　56　(2)　159-162　2019/09

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  41. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis. International-journal Peer-reviewed

    Saori Katayama, Mikiko Suzuki, Ayaka Yamaoka, Nadine Keleku-Lukwete, Fumiki Katsuoka, Akihito Otsuki, Shigeo Kure, James Douglas Engel, Masayuki Yamamoto

    Blood　130　(7)　908-919　2017/08/17

    DOI： 10.1182/blood-2016-12-756767 　

    More details Close

    Chromosomal rearrangements between 3q21 and 3q26 induce inappropriate EVI1 expression by recruiting a GATA2-distal hematopoietic enhancer (G2DHE) to the proximity of the EVI1 gene, leading to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The acquisition of G2DHE by the EVI1 gene reciprocally deprives this enhancer of 1 of the 2 GATA2 alleles, resulting in a loss-of-function genetic reduction in GATA2 abundance. Because GATA2 haploinsufficiency is strongly associated with MDS and AML, we asked whether EVI1 misexpression and GATA2 haploinsufficiency both contributed to the observed leukemogenesis by using a 3q21q26 mouse model that recapitulates the G2DHE-driven EVI1 misexpression, but in this case, it was coupled to a Gata2 heterozygous germ line deletion. Of note, the Gata2 heterozygous deletion promoted the EVI1-provoked leukemic transformation, resulting in early onset of leukemia. The 3q21q26 mice suffered from leukemia in which B220+ cells and/or Gr1+ leukemic cells occupied their bone marrows. We found that the B220+Gr1-c-Kit+ population contained leukemia-initiating cells and supplied Gr1+ leukemia cells in the 3q21q26 leukemia. When Gata2 expression levels in the B220+Gr1-c-Kit+ cells were decreased as a result of Gata2 heterozygous deletion or spontaneous phenomenon, myeloid differentiation of the B220+Gr1-c-Kit+ cells was suppressed, and the cells acquired induced proliferation as well as B-lymphoid-primed characteristics. Competitive transplantation analysis revealed that Gata2 heterozygous deletion confers selective advantage to EVI1-expressing leukemia cell expansion in recipient mice. These results demonstrate that both the inappropriate stimulation of EVI1 and the loss of 1 allele equivalent of Gata2 expression contribute to the acceleration of leukemogenesis.

  42. Derepression of the DNA Methylation Machinery of the Gata1 Gene Triggers the Differentiation Cue for Erythropoiesis. International-journal Peer-reviewed

    Lei Yu, Jun Takai, Akihito Otsuki, Fumiki Katsuoka, Mikiko Suzuki, Saori Katayama, Masahiro Nezu, James Douglas Engel, Takashi Moriguchi, Masayuki Yamamoto

    Molecular and cellular biology　37　(8)　2017/04/15

    DOI： 10.1128/MCB.00592-16 　

    More details Close

    GATA1 is a critical regulator of erythropoiesis. While the mechanisms underlying the high-level expression of GATA1 in maturing erythroid cells have been studied extensively, the initial activation of the Gata1 gene in early hematopoietic progenitors remains to be elucidated. We previously identified a hematopoietic stem and progenitor cell (HSPC)-specific silencer element (the Gata1 methylation-determining region [G1MDR]) that recruits DNA methyltransferase 1 (Dnmt1) and provokes methylation of the Gata1 gene enhancer. In the present study, we hypothesized that removal of the G1MDR-mediated silencing machinery is the molecular basis of the initial activation of the Gata1 gene and erythropoiesis. To address this hypothesis, we generated transgenic mouse lines harboring a Gata1 bacterial artificial chromosome in which the G1MDR was deleted. The mice exhibited abundant GATA1 expression in HSPCs, in a GATA2-dependent manner. The ectopic GATA1 expression repressed Gata2 transcription and induced erythropoiesis and apoptosis of HSPCs. Furthermore, genetic deletion of Dnmt1 in HSPCs activated Gata1 expression and depleted HSPCs, thus recapitulating the HSC phenotype associated with GATA1 gain of function. These results demonstrate that the G1MDR holds the key to HSPC maintenance and suggest that release from this suppressive mechanism is a fundamental requirement for subsequent initiation of erythroid differentiation.

  43. Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation. International-journal Peer-reviewed

    Nadine Keleku-Lukwete, Mikiko Suzuki, Akihito Otsuki, Kouhei Tsuchida, Saori Katayama, Makiko Hayashi, Eriko Naganuma, Takashi Moriguchi, Osamu Tanabe, James Douglas Engel, Masue Imaizumi, Masayuki Yamamoto

    Proceedings of the National Academy of Sciences of the United States of America　112　(39)　12169-74　2015/09/29

    DOI： 10.1073/pnas.1509158112 　

    More details Close

    Sickle cell disease (SCD) is an inherited disorder caused by a point mutation in the β-globin gene, leading to the production of abnormally shaped red blood cells. Sickle cells are prone to hemolysis and thereby release free heme into plasma, causing oxidative stress and inflammation that in turn result in damage to multiple organs. The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) is a master regulator of the antioxidant cell-defense system. Here we show that constitutive Nrf2 activation by ablation of its negative regulator Keap1 (kelch-like ECH-associated protein 1) significantly improves symptoms in SCD model mice. SCD mice exhibit severe liver damage and lung inflammation associated with high expression levels of proinflammatory cytokines and adhesion molecules compared with normal mice. Importantly, these symptoms subsided after Nrf2 activation. Although hemolysis and stress erythropoiesis did not change substantially in the Nrf2-activated SCD mice, Nrf2 promoted the elimination of plasma heme released by sickle cells' hemolysis and thereby reduced oxidative stress and inflammation, demonstrating that Nrf2 activation reduces organ damage and segregates inflammation from prevention of hemolysis in SCD mice. Furthermore, administration of the Nrf2 inducer CDDO-Im (2-cyano-3, 12 dioxooleana-1, 9 diene-28-imidazolide) also relieved inflammation and organ failure in SCD mice. These results support the contention that Nrf2 induction may be an important means to protect organs from the pathophysiology of sickle cell-induced damage.

  44. Mesenchymal chondrosarcoma diagnosed on FISH for HEY1-NCOA2 fusion gene. International-journal Peer-reviewed

    Kunihiko Moriya, Saori Katayama, Masaei Onuma, Takeshi Rikiishi, Masami Hosaka, Mika Watanabe, Tadashi Hasegawa, Yoji Sasahara, Shigeo Kure

    Pediatrics international : official journal of the Japan Pediatric Society　56　(5)　e55-7　2014/10

    DOI： 10.1111/ped.12407 　

    More details Close

    Mesenchymal chondrosarcoma (MC) is an extremely rare subtype of chondrosarcoma that has a small round-cell sarcoma with focal cartilaginous differentiation, often with a pericytomatous vascular pattern. The non-cartilaginous components are usually dominant, and such lesions might be confused with other small round-cell tumors. Recently, a tumor-specific HEY1-NCOA2 fusion gene was identified in MC. Here we report the case of a 9-year-old boy who was diagnosed with MC by detection of HEY1-NCOA2 fusion signals in almost 50% of tumor cells in tissue sections on fluorescence in situ hybridization (FISH). In this way, the tumor was definitively diagnosed as MC. This case suggests that the detection of the HEY1-NCOA2 fusion gene on FISH is of diagnostic value for MC.

  45. A case series of CAEBV of children and young adults treated with reduced-intensity conditioning and allogeneic bone marrow transplantation: a single-center study. International-journal Peer-reviewed

    Yuko Watanabe, Yoji Sasahara, Miki Satoh, Chung Yeng Looi, Saori Katayama, Tasuku Suzuki, Nobu Suzuki, Meri Ouchi, Satoshi Horino, Kunihiko Moriya, Yuka Nanjyo, Masaei Onuma, Hiroshi Kitazawa, Masahiro Irie, Hidetaka Niizuma, Toru Uchiyama, Takeshi Rikiishi, Satoru Kumaki, Masayoshi Minegishi, Taizo Wada, Akihiro Yachie, Shigeru Tsuchiya, Shigeo Kure

    European journal of haematology　91　(3)　242-8　2013/09

    DOI： 10.1111/ejh.12151 　

    More details Close

    BACKGROUND: Epstein-Barr virus (EBV)-infected T or NK cells cause chronic active EBV infection (CAEBV). Allogeneic hematopoietic stem cell transplantation (HSCT) is curative treatment for CAEBV patients. However, chemotherapy prior to HSCT and optimal conditioning regimen for allogeneic HSCT are still controversial. PATIENTS AND METHODS: We retrospectively analyzed five patients with CAEBV treated with reduced-intensity conditioning (RIC) consisted of fludarabine, cyclophosphamide, and low-dose total-body irradiation followed by allogeneic bone marrow transplantation in a single institute. Only one of five patients received chemotherapy prior to transplantation. We analyzed EBV-infected cells in a patient whose EBV load increased after HSCT by T-cell repertoire assay, separation of T-cell subpopulations, in situ hybridization and microsatellite analysis. RESULTS: All five patients achieved engraftment, complete chimera, and eradication of EBV load. All patients have been alive without any serious regimen-related toxicity for more than 16 months following HSCT. However, one patient transplanted from HLA-matched sibling donor developed clonal proliferation of CD4+ Vβ3+ T cells caused by monoclonal EBV infection on day 99 after transplantation. Further analysis revealed that the CD4+ Vβ3+ T cells selectively harbored EBV genome, and these infected cells were derived from donor T cells. CONCLUSIONS: Allogeneic HSCT with RIC is a safe and effective treatment for better overall survival and less regimen-related toxicity in patients with CAEBV. Our first pediatric case reported in the literature suggests that we should consider the possibility of persistent EBV infection in donor T cells as well as the relapse in recipient cells if EBV load increases after allogeneic HSCT.

  46. Lower back pain as a symptom of migrainous corpalgia. International-journal Peer-reviewed

    Yosuke Kakisaka, Tomoichiro Ohara, Saori Katayama, Tasuku Suzuki, Naomi Hino-Fukuyo, Mitsugu Uematsu, Shigeo Kure

    Journal of child neurology　28　(5)　676-7　2013/05

    DOI： 10.1177/0883073813478170 　

    More details Close

    The symptoms and prevalence of migraine headaches are widely recognized; however, less is known about migraine-related spontaneous body pain, or migrainous corpalgia. Only a few reports have described it. The case of a 13-year-old boy with onset of migrainous corpalgia at the age of 12 years is presented. He suffered from pulsatile headaches and bilateral lower back pain, which would appear either with the headache or as an isolated symptom. Various medical examinations showed no abnormalities. He was diagnosed as having migraine without aura and successfully treated with valproic acid. It is unique for this patient to have lower back pain as a symptom of migrainous corpalgia. It would be important for physicians to understand the variety of pain symptoms in migraine patients, as shown here, for better and comprehensive understanding of migraine and its related condition.

  47. Another case of lower back pain associated with migraine: the importance of specific questions. International-journal Peer-reviewed

    Yosuke Kakisaka, Tomoichiro Ohara, Saori Katayama, Tasuku Suzuki, Naomi Hino-Fukuyo, Mitsugu Uematsu, Shigeo Kure

    Journal of child neurology　28　(5)　680-680　2013/05

    DOI： 10.1177/0883073813483366 　

  48. Human herpes virus type 6 can cause skin lesions at the BCG inoculation site similar to Kawasaki Disease. Peer-reviewed

    Yosuke Kakisaka, Tomoichiro Ohara, Saori Katayama, Tasuku Suzuki, Shu Sasai, Naomi Hino-Fukuyo, Shigeo Kure

    The Tohoku journal of experimental medicine　228　(4)　351-3　2012/12

    eISSN： 1349-3329

    More details Close

    Kawasaki Disease (KD) is acute, febrile, multisystem vasculitis of early childhood, the detailed mechanism of which is still unclear. Skin symptoms occur in KD, such as edema of the hands and feet with subsequent desquamation and redness at the inoculation site of bacillus Calmette-Guerin (BCG). The change at the BCG inoculation site has been considered as a specific feature of KD, although its mechanism is not fully understood. We present an 11-month-old boy who developed fever with redness of the BCG site due to infection with human herpes virus type 6 (HHV6). At the age of 3 months, the patient received BCG. His fever remitted 7 days after the onset of skin redness, with sequential desquamation at the BCG site and extremities, which is not a common feature of HHV6 infection that typically lasts for 3 days. The final diagnosis was exanthema subitum. Characteristically, the HHV6 infection in our patient appeared to be associated with the invigoration of the T cell system, as represented by the elevated serum levels of soluble interleukin-2 receptor (3,490 U/ml vs. normal range 145-519 U/ml). This patient clearly showed redness and crusting at the BCG inoculation site, suggesting that HHV6 infection might cause skin changes similar to those of KD via an unknown mechanism. In addition, we suggest that the activation of the T cell system may account for the skin lesions in KD, characterized by redness and subsequent crusting of the BCG inoculation site and desquamation of the extremities.

  49. Panax ginseng: a newly identified cause of gynecomastia. Peer-reviewed

    Yosuke Kakisaka, Tomoichiro Ohara, Hideo Tozawa, Shun Sato, Saori Katayama, Tasuku Suzuki, Naomi Hino-Fukuyo, Shigeo Kure

    The Tohoku journal of experimental medicine　228　(2)　143-5　2012/10

    eISSN： 1349-3329

    More details Close

    Gynecomastia or benign proliferation of the male breast glandular tissue is not uncommon for adolescent males. Its pathogenesis has been attributed to a transient imbalance between estrogens and androgens. Ginseng is a popular herb with a long history of medicinal use. Oriental folk medicine describes it as both a tonic for restoring strength and a panacea. The term "ginseng" generally refers to a plant, Panax ginseng. Based on estrogen-like actions of Panax ginseng due to its structural similarity with estradiol, this agent could be speculated to cause gynecomastia. Here we report a 12-year-old Korean-Japanese boy with bilateral enlargement of the breasts with tenderness in the right breast, which was noticed about 1 month before his first visit to our outpatient clinic. He was diagnosed with gynecomastia based on physical, laboratory, and ultrasound examinations. Detailed questioning about his medications and supplements revealed that he had been given red ginseng extract daily to enhance his performance for 1 month before his clinical presentation. He wanted to make his body stronger as an athlete. He was recommended from his grandmother to take Panax ginseng for his purpose. After stopping this, there was no further growth of the masses and no pain when his right breast was pressed. In conclusion, physicians should consider ginseng in the investigation of gynecomastia.

Show all ︎Show first 5

Misc. 82

  1. Outcome of chemotherapy dose reduction in overweight Japanese children with acute lymphoblastic leukemia

    Saori Katayama, Kunihiko Moriya, Toshihiko Imamura, Kosuke Tamefusa, Kimiyoshi Sakaguchi, Takashi Ishihara, Masanori Nishi, Ikuya Usami, Asahito Hama, Daiichiro Hasegawa, Atsushi Sato, Souichi Suenobu, Akiko Moriya-Saito, Keizo Horibe, Junichi Hara

    INTERNATIONAL JOURNAL OF HEMATOLOGY　2025/11/10

    DOI： 10.1007/s12185-025-04103-z 　

    ISSN： 0925-5710

    eISSN： 1865-3774

  2. 後腹膜悪性末梢神経鞘腫に伴う片側尿管狭窄により腎後性腎不全を呈した一例

    三浦拓人, 三浦拓人, 内田奈生, 片山紗乙莉, 入江正寛, 菊池敦生

    日本小児腎臓病学会雑誌(Web)　38　2025

    ISSN： 1881-3933

  3. Chimeric antigen receptor(CAR)-T細胞療法後にCD19陰性幼若B細胞を認め残存病変評価に苦慮した症例

    大久保 礼由, 石塚 静江, 真山 晃史, 吉岡 翔, 清水 夏海, 鈴木 千恵, 菅原 新吾, 入江 正寛, 片山 紗乙莉, 加藤 浩貴, 亀井 尚

    Cytometry Research　34　(Suppl.)　70-70　2024/07

    Publisher: (一社)日本サイトメトリー学会

    ISSN： 0916-6920

    eISSN： 2424-0664

  4. 肉眼的血尿と紫斑を主訴とし,Evans症候群と膜性腎症を合併した幼児例

    森ひろみ, 内田奈生, 中野智太, 鈴木資, 片山紗乙莉, 入江正寛, 新妻秀剛, 笹原洋二, 菊池敦生

    日本小児腎臓病学会雑誌(Web)　37　2024

    ISSN： 1881-3933

  5. 治療後遠隔期に中枢神経外多発骨・骨髄転移再発を来した髄芽腫の一例

    戒能明, 入江正寛, 岩淵蒼太, 中野智太, 鈴木資, 片山紗乙莉, 新妻秀剛, 下田由輝, 金森政之, 遠藤英徳, 笹原洋二, 菊池敦生

    日本小児血液・がん学会雑誌(Web)　61　(1)　2024

    ISSN： 2189-5384

  6. 肝芽腫を発症した21モノソミーモザイクの女児

    庄司理以沙, 片山紗乙莉, 諸田真莉子, 中野智太, 鈴木資, 入江正寛, 新妻秀剛, 笹原洋二, 菊池敦生

    日本小児血液・がん学会雑誌(Web)　60　(2)　2023

    ISSN： 2189-5384

  7. HOW PALLIATIVE CARE TEAM SUPPORT US PEDIATRICIANS. CASE REPORTS AND COOPERATIVE WORKS FROM TOHOKU UNIVERSITY HOSPITAL

    Akira Kaino, Keita Tagami, Mamiko Sato, Saori Katayama, Tasuku Suzuki, Kunihiko Moriya, Masahiro Irie, Hidetaka Niizuma, Akira Inoue, Yoji Sasahara

    PEDIATRIC BLOOD & CANCER　69　2022/11

    ISSN： 1545-5009

    eISSN： 1545-5017

  8. 術前化学療法を施行した両側性Wilms腫瘍の2例

    中村 春彦, 入江 正寛, 片山 紗乙莉, 森谷 邦彦, 力石 健, 新妻 秀剛, 笹原 洋二, 呉 繁夫

    日本小児血液・がん学会雑誌　59　(2)　202-203　2022/07

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  9. 術前化学療法を施行した両側性Wilms腫瘍の2例

    中村春彦, 入江正寛, 片山紗乙莉, 森谷邦彦, 力石健, 新妻秀剛, 笹原洋二, 呉繁夫

    日本小児血液・がん学会雑誌(Web)　59　(2)　2022

    ISSN： 2189-5384

  10. How palliative care team support us pediatricians. Case reports and cooperative works from Tohoku University Hospital

    KAINO Akira, TAGAMI Keita, SATO Mamiko, KATAYAMA Saori, SUZUKI Tasuku, MORIYA Kunihiko, IRIE Masahiro, NIIZUMA Hidetaka, INOUE Akira, SASAHARA Yoji

    日本小児血液・がん学会雑誌(Web)　59　(4)　2022

    ISSN： 2189-5384

  11. 化学療法後好中球減少症を合併し画像診断により肛門周囲感染症を疑った1例

    目黒美結, 森谷邦彦, 崔実結, 戒能明, 片山紗乙莉, 鈴木資, 入江正寛, 新妻秀剛, 笹原洋二, 呉繁夫

    小児科　63　(2)　2022

    ISSN： 0037-4121

  12. Incidence of symptomatic ON in pediatric ALL treated with BFM based protocol is similar to children in western countries

    森谷邦彦, 今村俊彦, 片山紗乙莉, 戒能明, 岡本賢治, 横山能文, 植村優, 北澤宏展, 関水匡大, 平松英文, 長谷川大一郎, 濱麻人, 齋藤明子, 佐藤篤, 笹原洋二, 末延聡一, 堀部敬三, 原純一

    日本小児科学会雑誌　126　(2)　2022

    ISSN： 0001-6543

  13. A Case Report of 8 Year-Old Girl with MDS, Suffering from SOS After Allogeneic BMT, Followed by Post-Transplantation Thrombocytopenia

    Masahiro Irie, Yoji Sasahara, Tomohiro Nakano, Tasuku Suzuki, Saori Katayama, Kunihiko Moriya, Hidetaka Niizuma, Takeshi Rikiishi, Masashi Hirayama, Shigeo Kure

    PEDIATRIC BLOOD & CANCER　68　2021/11

    ISSN： 1545-5009

    eISSN： 1545-5017

  14. Infantile-Onset Fulminant Type 1 Diabetes Mellitus Caused by Novel Compound Heterozygous Lrba Variants

    Akira Kaino, Kunihiko Moriya, Tomohiro Nakano, Daichi Sato, Saori Katayama, Hidetaka Niizuma, Yoji Sasahara, Shigeo Kure

    PEDIATRIC BLOOD & CANCER　68　2021/11

    ISSN： 1545-5009

    eISSN： 1545-5017

  15. Age at Diagnosis and Prognosis of Retinoblastoma: A Retrospective Single Center Observational Study

    Miyu Sai, Hidetaka Niizuma, Masahiro Irie, Kunihiko Moriya, Saori Katayama, Tasuku Suzuki, Yoji Sasahara, Shigeo Kure

    PEDIATRIC BLOOD & CANCER　68　2021/11

    ISSN： 1545-5009

    eISSN： 1545-5017

  16. Age at diagnosis and prognosis of retinoblastoma: a retrospective single center observational study

    SAI Miyu, NIIZUMA Hidetaka, IRIE Masahiro, MORIYA Kunihiko, KATAYAMA Saori, SUZUKI Tasuku, SASAHARA Yoji, KURE Shigeo

    日本小児血液・がん学会雑誌(Web)　58　(4)　2021

    ISSN： 2189-5384

  17. A pediatric case of osteosarcoma and tuberous sclerosis complex with a somatic mutation in the TP53 gene

    MORIYA Kunihiko, SATO Daichi, NAKANO Tomohiro, WATANUKI Munenori, KATAYAMA Saori, NIIZUMA Hidetaka, SASAHARA Yoji, KURE Shigeo

    日本小児血液・がん学会雑誌(Web)　58　(4)　2021

    ISSN： 2189-5384

  18. A case report of 8 year-old girl with MDS, suffering from SOS after allogeneic BMT, followed by post-transplantation thrombocytopenia

    IRIE Masahiro, SASAHARA Yoji, NAKANO Tomohiro, SUZUKI Tasuku, KATAYAMA Saori, MORIYA Kunihiko, NIIZUMA Hidetaka, RIKIISHI Takeshi, HIRAYAMA Masashi, KURE Shigeo

    日本小児血液・がん学会雑誌(Web)　58　(4)　2021

    ISSN： 2189-5384

  19. Ataxia-telangiectasia with refractory diffuse large B cell lymphoma caused by novel compound heterozygous ATM variants

    SATO Daichi, MORIYA Kunihiko, NAKANO Tomohiro, KATAYAMA Saori, NIIZUMA Hidetaka, SASAHARA Yoji, KURE Shigeo

    日本小児血液・がん学会雑誌(Web)　58　(4)　2021

    ISSN： 2189-5384

  20. LRBA deficiency presenting with infantile fulminant type I diabetes mellitus

    森谷邦彦, 戸恒恵理子, 中野智太, 佐藤大地, 片山紗乙莉, 新妻秀剛, 笹原洋二, 呉繁夫

    日本血液学会学術集会抄録(Web)　83rd　2021

  21. Clinical Sequencing Revealed Two Distinct Mutations in SMARCB1, in an INI-1 Positive AT/RT

    Akira Kaino, Hidetaka Niizuma, Kunihiko Moriya, Saori Katayama, Masahiro Irie, Takeshi Rikiishi, Ryuta Saito, Masayuki Kanamori, Yoji Sasahara, Shigeo Kure

    PEDIATRIC BLOOD & CANCER　67　2020/12

    ISSN： 1545-5009

    eISSN： 1545-5017

  22. Genetic Analysis of an Early T-Cell Precursor Acute Lymphoblastic Lymphoma Associated with Myeloproliferative Neoplasm

    Saori Katayama, Tomohiro Nakano, Masahiro Irie, Kunihiko Moriya, Hidetaka Niizuma, Takeshi Rikiishi, Yoji Sasahara, Shigeo Kure

    PEDIATRIC BLOOD & CANCER　67　2020/12

    ISSN： 1545-5009

    eISSN： 1545-5017

  23. Clinical Sequencing of 20 Pediatric Solid Tumors: Utility for Molecular Diagnosis and Targeted Therapy

    Hidetaka Niizuma, Akira Kaino, Tomohiro Nakano, Saori Katayama, Kunihiko Moriya, Masahiro Irie, Takeshi Rikiishi, Yoji Sasahara, Shigeo Kure

    PEDIATRIC BLOOD & CANCER　67　2020/12

    ISSN： 1545-5009

    eISSN： 1545-5017

  24. 【原発性免疫不全症候群-最新の疾患分類と新規疾患を中心に-】免疫系以外の症状を呈する、あるいは症候群を呈する複合免疫不全症 Other Defects Activating de novo mutations in nuclear factor,erythroid 2-like2(NFE2L2)

    片山 紗乙莉

    日本臨床　78　(増刊7 原発性免疫不全症候群)　152-154　2020/12

    Publisher: (株)日本臨床社

    ISSN： 0047-1852

  25. 髄芽腫の放射線療法中に合併した難治性ITPに対し,rituximabが奏功した一例

    戒能 明, 新妻 秀剛, 入江 正寛, 片山 紗乙莉, 森谷 邦彦, 力石 健, 齋藤 竜太, 金森 政之, 笹原 洋二, 呉 繁夫

    日本小児科学会雑誌　124　(2)　321-321　2020/02

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  26. Clinical sequencing revealed two distinct mutations in SMARCB1, in an INI-1 positive AT/RT

    KAINO Akira, NIIZUMA Hidetaka, MORIYA Kunihiko, KATAYAMA Saori, IRIE Masahiro, RIKIISHI Takeshi, SAITO Ryuta, KANAMORI Masayuki, SASAHARA Yoji, KURE Shigeo

    日本小児血液・がん学会雑誌(Web)　57　(4)　2020

    ISSN： 2189-5384

  27. 再生不良性貧血に対し同胞間骨髄移植後播種性Fusarium感染症を呈した1例

    森谷邦彦, 片山紗乙莉, 南條由佳, 小沼正栄, 力石健, 新妻秀剛, 高橋隼也, 山崎研志, 笹原洋二, 呉繁夫

    日本血液学会学術集会抄録(Web)　82nd　2020

  28. Two cases of Wiskott-Aldrich syndrome complicated with diffuse large B cell lymphoma

    中野智太, 片山紗乙莉, 森谷邦彦, 入江正寛, 新妻秀剛, 力石健, 笹原洋二, 呉繁夫

    日本免疫不全・自己炎症学会総会・学術集会プログラム・抄録集　3rd　2020

  29. がん遺伝子パネル検査の時代を迎えて 治療に直結した2例の報告

    新妻 秀剛, 片山 紗乙莉, 森谷 邦彦, 渡辺 祐子, 入江 正寛, 力石 健, 新堀 哲也, 青木 洋子, 末原 義之, 加藤 俊介, 笹原 洋二, 呉 繁夫

    日本小児科学会雑誌　124　(1)　99-99　2020/01

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  30. 左前腕腫脹で発症した好酸球性肉芽腫の幼児例

    萩原基実, 森谷邦彦, 片山紗乙莉, 入江正寛, 力石健, 新妻秀剛, 笹原洋二, 呉繁夫

    小児科　61　(13)　2020

    ISSN： 0037-4121

  31. がん遺伝子パネル検査の時代を迎えて 治療に直結した2例の報告

    新妻 秀剛, 片山 紗乙莉, 森谷 邦彦, 渡辺 祐子, 入江 正寛, 力石 健, 新堀 哲也, 青木 洋子, 末原 義之, 加藤 俊介, 笹原 洋二, 呉 繁夫

    日本小児科学会雑誌　124　(1)　99-99　2020/01

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  32. A Report of a PatientWith CD30 Positive PMLBL, Relapsed After Multimodality Therapy, Successfully Treated With Brentuximab Vedotin Monotherapy

    Masahiro Irie, Mika Watanabe, Saori Katayama, Kunihiko Moriya, Yuko Watanabe, Hidetaka Niizuma, Takeshi Rikiishi, Yoji Sasahara, Shigeo Kure

    PEDIATRIC BLOOD & CANCER　66　S43-S44　2019/12

    ISSN： 1545-5009

    eISSN： 1545-5017

  33. Clinical Sequencing Revealed the ALK-Related Fusion Gene in an Infantile Soft Tissue Sarcoma, Leading to Molecular Diagnosis and ALK-Targeted Therapy

    Akira Kaino, Hidetaka Niizuma, Yoshiyuki Suehara, Saori Katayama, Shunsuke Kato, Tsuyoshi Saito, Takuo Hayashi, Kunihiko Moriya, Masahiro Irie, Takeshi Rikiishi, Yoji Sasahara, Shigeo Kure

    PEDIATRIC BLOOD & CANCER　66　S98-S98　2019/12

    ISSN： 1545-5009

    eISSN： 1545-5017

  34. 再発CD30陽性縦隔原発大細胞性B細胞性リンパ腫(PMLBL)に対してbrentuximab vedotin単剤療法が著効した1例

    入江 正寛, 中野 智太, 片山 紗乙莉, 森谷 邦彦, 渡辺 祐子, 新妻 秀剛, 力石 健, 笹原 洋二, 呉 繁夫, 渡辺 みか

    臨床血液　60　(11)　1593-1593　2019/11

    Publisher: (一社)日本血液学会-東京事務局

    ISSN： 0485-1439

    eISSN： 1882-0824

  35. 多発肺転移をきたした肝芽腫の1例

    鈴木 聡志, 片山 紗乙莉, 渡辺 祐子, 入江 正寛, 新妻 秀剛, 力石 健, 笹原 洋二, 呉 繁夫, 福澤 太一, 仁尾 正記

    日本小児血液・がん学会雑誌　56　(2)　269-269　2019/09

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  36. Wiskott-Aldrich症候群に合併した全身性自己免疫性炎症にRituximabが奏効した一例

    中野 智太, 新妻 秀剛, 片山 紗乙莉, 渡辺 祐子, 入江 正寛, 力石 健, 笹原 洋二, 呉 繁夫

    日本小児血液・がん学会雑誌　56　(2)　221-224　2019/09

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  37. 多発肺転移をきたした肝芽腫の1例

    鈴木 聡志, 片山 紗乙莉, 渡辺 祐子, 入江 正寛, 新妻 秀剛, 力石 健, 笹原 洋二, 呉 繁夫, 福澤 太一, 仁尾 正記

    日本小児血液・がん学会雑誌　56　(2)　269-269　2019/09

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  38. 自己免疫症状に対してリツキシマブを使用したWiskott-Aldrich症候群の3例

    片山 紗乙莉, 渡辺 祐子, 入江 正寛, 新妻 秀剛, 力石 健, 笹原 洋二, 呉 繁夫

    日本小児科学会雑誌　123　(2)　509-509　2019/02

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  39. 両側腎浸潤と軽度水腎を認め急性腎不全に陥ったBurkittリンパ腫の1例

    内田 奈生, 高橋 俊成, 阿部 雄紀, 吉田 茉莉恵, 片山 紗乙莉, 鈴木 資, 渡辺 祐子, 入江 正寛, 新妻 秀剛, 熊谷 直憲, 力石 健, 笹原 洋二, 呉 繁夫

    日本小児腎不全学会雑誌　38　174-177　2018/07

    Publisher: 日本小児腎不全学会

    ISSN： 1341-5875

  40. 急性心不全にて腎芽腫を発症した3ヵ月女児の一例

    安齋 豪人, 入江 正寛, 西條 直也, 山田 瑛子, 片山 紗乙莉, 川野 研悟, 渡辺 祐子, 菅原 典子, 新妻 秀剛, 力石 健, 笹原 洋二, 呉 繁夫, 山木 聡史, 風間 理郎, 仁尾 正記, 鈴木 信, 稲垣 徹史

    日本小児血液・がん学会雑誌　55　(2)　213-213　2018/07

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  41. 尿細管間質性腎炎を合併したSTAT1機能獲得変異による慢性皮膚粘膜カンジダ症

    内田 奈生, 高橋 俊成, 佐々木 太郎, 鈴木 資, 片山 紗乙莉, 渡辺 祐子, 菊池 敦生, 菅原 典子, 入江 正寛, 新妻 秀剛, 力石 健, 熊谷 直憲, 笹原 洋二, 呉 繁夫, 佐藤 博, 城 謙輔

    日本小児科学会雑誌　122　(2)　398-398　2018/02

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  42. 小児血液・腫瘍入院患者の傾向と、診断まで時間のかかった症例の検討

    新妻 秀剛, 鈴木 資, 片山 紗乙莉, 渡辺 祐子, 入江 正寛, 力石 健, 笹原 洋二, 呉 繁夫, 齋藤 竜太, 金森 政之, 風間 理郎, 綿貫 宗則, 保坂 正美

    日本小児科学会雑誌　122　(1)　93-93　2018/01

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  43. 尿崩症の原因としてLCHを認めた5歳女児の1例

    松橋 徹郎, 菅野 潤子, 高橋 俊成, 川嶋 明香, 鈴木 大, 片山 紗乙莉, 内田 奈央, 市野井 那津子, 上村 美季, 渡辺 祐子, 入江 正寛, 新妻 秀剛, 力石 健, 熊谷 直憲, 笹原 洋二, 藤原 幾磨, 呉 繁夫, 箱田 明子, 河野 秀信

    日本小児科学会雑誌　122　(1)　94-95　2018/01

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  44. Brentuximab vedotinで再寛解に至ったが急性膵炎を合併した再発性未分化大細胞性リンパ腫の一例

    前原 菜美子, 新妻 秀剛, 鈴木 資, 片山 紗乙莉, 渡辺 祐子, 入江 正寛, 力石 健, 渡辺 みか, 笹原 洋二, 呉 繁夫

    日本小児血液・がん学会雑誌　54　(3)　262-266　2017/12

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  45. 3番染色体転座・逆位を伴う白血病におけるGATA2遺伝子発現減少の貢献

    鈴木 未来子, 山岡 彩香, 片山 紗乙莉, 山本 雅之

    生命科学系学会合同年次大会　2017年度　[2P-0884]　2017/12

    Publisher: 生命科学系学会合同年次大会運営事務局

  46. Clinical and Genetic Analysis of two Patients with ACTH Unresponsiveness, NK Cell Deficiency and Diffuse Large B Cell Lymphoma

    Yoji Sasahara, Tomohiro Nakano, Saori Katayama, Tasuku Suzuki, Yuko Watanabe, Masahiro Irie, Hidetaka Niizuma, Takeshi Rikiishi, Shigeo Kure

    PEDIATRIC BLOOD & CANCER　64　S41-S41　2017/11

    ISSN： 1545-5009

    eISSN： 1545-5017

  47. A report of 2 Patients with Therapy-refractory Langerhans Cell Histiocytosis (LCH) who were Successfully Treated with Monotherapy of Clofarabine

    Masahiro Irie, Tomohiro Nakano, Tasuku Suzuki, Saori Katayama, Yuko Watanabe, Hidetaka Niizuma, Takeshi Rikiishi, Yoji Sasahara, Shigeo Kure

    PEDIATRIC BLOOD & CANCER　64　S34-S35　2017/11

    ISSN： 1545-5009

    eISSN： 1545-5017

  48. 先天性心疾患に対するFontan型手術後の患者に発生したEwing肉腫の治療経験

    前原 菜美子, 新妻 秀剛, 鈴木 資, 片山 紗乙莉, 渡辺 祐子, 入江 正寛, 木村 正人, 力石 健, 笹原 洋二, 呉 繁夫

    日本小児血液・がん学会雑誌　54　(2)　185-185　2017/06

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  49. GATA2遺伝子ヘテロ欠失は3番染色体逆位を伴う白血病の発症を促進する

    片山 紗乙莉, 鈴木 未来子, 呉 繁夫, 山本 雅之

    日本生化学会大会プログラム・講演要旨集　89回　[2T07-299)]　2016/09

    Publisher: (公社)日本生化学会

  50. Keap1-Nrf2 System: Potential Role in Prevention of Sickle Cell Disease Organs Damages and Inflammation

    Nadine Keleku-Lukwete, Mikiko Suzuki, Akihito Otsuki, Kouhei Tsuchida, Saori Katayama, Makiko Hayashi, Eriko Naganuma, Takashi Moriguchi, Osamu Tanabe, James Doug Engel, Masue Imaizumi, Masayuki Yamamoto

    BLOOD　126　(23)　2015/12

    ISSN： 0006-4971

    eISSN： 1528-0020

  51. SIOPEL-4プロトコールで治療を行った肺転移を伴う肝芽腫の1例

    風間 理郎, 力石 健, 入江 正寛, 田中 拡, 工藤 博典, 川岸 直樹, 和田 基, 佐々木 英之, 西 功太郎, 中村 恵美, 小沼 正栄, 渡辺 祐子, 森谷 邦彦, 片山 紗乙莉, 笹原 洋二, 仁尾 正記

    日本小児血液・がん学会雑誌　52　(1)　71-71　2015/03

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  52. Growing Teratoma syndromeと鑑別を要した卵巣原発未熟奇形腫の1例

    森谷 邦彦, 矢尾板 久雄, 片山 紗乙莉, 小沼 正栄, 入江 正寛, 力石 健, 笹原 洋二, 風間 理郎, 佐々木 英之, 和田 基, 仁尾 正記, 呉 繁夫

    日本小児血液・がん学会雑誌　52　(1)　73-73　2015/03

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  53. アレイCGH法にてiAMP21を同定したTEL-AML1融合遺伝子陽性骨原発悪性リンパ腫の1例(iAMP21 detected by array-based comparative genomic hybridization in a patient with TEL-AML1 bone lymphoma)

    森谷 邦彦, 片山 紗乙莉, 小沼 正栄, 市野井 那津子, 菊池 敦生, 力石 健, 笹原 洋二, 呉 繁夫

    日本小児血液・がん学会雑誌　51　(4)　225-225　2014/10

    Publisher: (一社)日本小児血液・がん学会

    ISSN： 2187-011X

    eISSN： 2189-5384

  54. EVI1陽性白血病においてEVI1発現量が白血病細胞の分化形態を規定する

    鈴木 未来子, 片山 紗乙莉, 山嵜 博未, Engel James Douglas, 山本 雅之

    日本生化学会大会プログラム・講演要旨集　87回　[3P-420]　2014/10

    Publisher: (公社)日本生化学会

  55. 目で見る小児科 両手爪の剥離を初発症状としたLangerhans細胞組織球症の1例

    森谷 邦彦, 片山 紗乙莉, 小沼 正栄, 力石 健, 笹原 洋二, 呉 繁夫

    小児科　55　(9)　1243-1244　2014/08

    Publisher: 金原出版(株)

    ISSN： 0037-4121

  56. 骨原発の悪性リンパ腫を発症した5歳女児例

    新妻 創, 片山 紗乙莉, 森谷 邦彦, 小沼 正栄, 内山 徹, 笹原 洋二, 呉 繁夫

    日本小児科学会雑誌　118　(4)　731-731　2014/04

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  57. Growing Teratoma syndromeと鑑別を要した卵巣原発未熟奇形腫の1例

    矢尾板 久雄, 森谷 邦彦, 片山 紗乙莉, 小沼 正栄, 入江 正寛, 力石 健, 笹原 洋二, 風間 理郎, 佐藤 智行, 佐々木 英之, 和田 基, 仁尾 正記, 呉 繁夫

    日本小児科学会雑誌　118　(3)　579-579　2014/03

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  58. 頸部腫脹とアミラーゼ上昇を来した川崎病の1例 超音波検査の可能性

    鈴木 資, 柿坂 庸介, 佐々木 和人, 片山 紗乙莉, 大原 朋一郎

    小児科臨床　67　(1)　135-139　2014/01

    Publisher: (株)日本小児医事出版社

    ISSN： 0021-518X

  59. 宮城県立こども病院における急性リンパ性白血病の治療成績

    島 彦仁, 片山 紗乙莉, 大内 芽里, 堀野 智史, 南條 由佳, 入江 正寛, 小沼 正栄, 星 能元, 藤井 邦裕, 武山 淳二, 佐藤 篤, 今泉 益栄

    日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号　55回・11回・18回　247-247　2013/11

    Publisher: (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会

  60. HEY1-NCOA2融合シグナルの検出が診断に有効であった間葉系軟骨肉腫の1例

    森谷 邦彦, 片山 紗乙莉, 鈴木 信, 小沼 正栄, 入江 正寛, 力石 健, 笹原 洋二, 綿貫 宗則, 保坂 正美, 渡辺 みか, 長谷川 匡, 呉 繁夫

    日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号　55回・11回・18回　274-274　2013/11

    Publisher: (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会

  61. 特徴的な症状を呈した片頭痛の小児例

    片山 紗乙莉, 柿坂 庸介, 佐々木 和人, 鈴木 資, 大原 朋一郎, 呉 繁夫

    小児科臨床　66　(10)　2055-2060　2013/10

    Publisher: (株)日本小児医事出版社

    ISSN： 0021-518X

  62. WASPとIL-10受容体遺伝子変異を同定した乳児期発症炎症性腸疾患2症例の臨床的検討

    笹原 洋二, 大内 芽里, 鈴木 信, 鈴木 資, 片山 紗乙莉, 入江 正寛, 呉 繁夫, 浅田 洋司, 角田 文彦, 虻川 大樹

    日本小児科学会雑誌　117　(2)　328-328　2013/02

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  63. 寛解導入療法から強い治療抵抗性を示したmyeloid抗原陽性T-ALLの1例

    佐藤 篤, 及川 善嗣, 片山 紗乙莉, 南條 由佳, 入江 正寛, 今泉 益栄

    日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号　54回・10回・17回　314-314　2012/11

    Publisher: (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会

  64. 橈骨尺骨癒合を伴う無巨核球性血小板減少症の乳児に対し、骨髄非破壊的前処置にて臍帯血移植を施行した一例

    入江 正寛, 佐藤 篤, 片山 紗乙莉, 齋籐 由佳, 高橋 立子, 今泉 益栄

    日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号　54回・10回・17回　372-372　2012/11

    Publisher: (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会

  65. 母体に投与された硫酸マグネシウムの新生児電解質への影響

    内田 俊彦, 片山 紗乙莉, 渡辺 哲, 饗場 智, 渡辺 真央

    日本小児科学会雑誌　116　(5)　878-878　2012/05

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  66. 交換輸血を行い救命し得た全身型HSV感染症に伴う血球貪食症候群の1例

    木越 隆晶, 今野 昭宏, 青木 倉揚, 片山 紗乙莉, 渡辺 哲, 内田 俊彦, 鈴木 恵美子, 柏原 俊彦, 饗場 智, 藤山 純一, 渡辺 真史

    日本小児科学会雑誌　116　(3)　608-608　2012/03

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  67. Sky法にて芽球染色体転座を同定できた小児成熟B細胞性白血病の1例

    片山 紗乙莉, 大内 芽里, 入江 正寛, 星 能元, 佐藤 篤, 今泉 益栄, 浅田 洋司

    日本小児科学会雑誌　116　(3)　608-608　2012/03

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  68. 極低出生体重児における血清亜鉛値とおむつ皮膚炎の関連

    内田 俊彦, 片山 紗乙莉, 内田 奈生

    日本未熟児新生児学会雑誌　24　(1)　139-142　2012/02

    Publisher: (公社)日本新生児成育医学会

    ISSN： 1347-8540

  69. 集学的治療の有用性が示唆された難治性Kasabach-Merritt症候群の一例

    片山 紗乙莉, 入江 正寛, 大内 芽里, 佐藤 篤, 今泉 益栄, 佐藤 智樹, 齊藤 潤子, 北見 昌広, 島貫 義久, 神宮 啓一

    日本小児科学会雑誌　116　(2)　309-309　2012/02

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  70. SKY法が複雑型染色体異常の同定に有用であった急性白血病の2例

    片山 紗乙莉, 小沼 正栄, 内山 徹, 新妻 秀剛, 力石 健, 笹原 洋二, 呉 繁夫

    小児がん　48　(プログラム・総会号)　204-204　2011/11

    Publisher: (NPO)日本小児がん学会

    ISSN： 0389-4525

  71. 1ヵ月健診時の授乳状況

    内田 俊彦, 青木 倉揚, 木越 隆晶, 片山 紗乙莉, 渡辺 哲, 饗場 智, 渡辺 真史

    日本小児科学会雑誌　115　(9)　1472-1472　2011/09

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  72. 極低出生体重児への亜鉛投与と皮膚症状

    内田 俊彦, 木越 隆晶, 青木 倉揚, 片山 紗乙莉, 渡辺 哲, 饗場 智, 渡辺 真史

    日本小児科学会雑誌　115　(9)　1477-1477　2011/09

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  73. 当院での過去5年間のHib髄膜炎の報告

    柏原 俊彦, 片山 紗乙莉, 鈴木 恵美子, 渡辺 哲, 内田 俊彦, 今野 昭宏, 饗場 智, 渡辺 真史, 藤山 純一

    日本小児科学会雑誌　115　(7)　1274-1274　2011/07

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  74. 在胎22週5日、体重322gで出生し、無事退院した超低出生体重児

    内田 俊彦, 片山 紗乙莉, 早川 裕子, 渡辺 哲, 饗場 智, 渡辺 真史

    山形県立病院医学雑誌　45　(2)　158-160　2011/07

    Publisher: 山形県病医誌編集委員会

    ISSN： 0389-0848

    More details Close

    臍帯血流低下と子宮内発育遅延のために在胎22週5日に緊急帝王切開で出生した女児症例について検討した。出生体重は322g、Apgar Scoreは1(1分)/2(5分)で、呼吸窮迫症候群のためにサーファクタント補充療法と人工呼吸管理を要した。胎便排泄は良好であったが、胎便塞栓予防に日齢3からグリセリン浣腸を開始した。日齢4にはビフィズス菌製剤と母乳を開始した。しかし、動脈管開存症と晩期循環不全を合併し、水分管理に難渋し、体重増加は緩慢となった。修正52週0日、体重2770gで退院した。修正10ヵ月で体重5166g、身長65.2cmとなり、座位保持可能であった。

  75. 修正40週前後の血清亜鉛値と在胎週数、出生体重、出生後の体重増加の関連性

    木越 隆晶, 内田 奈生, 内田 俊彦, 青木 倉揚, 片山 紗乙莉, 早川 裕子, 渡辺 哲, 饗場 智, 渡辺 真史

    日本小児科学会雑誌　115　(2)　312-312　2011/02

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  76. 小児重症細菌感染症におけるプロカルシトニン測定の有用性と盲点について

    鈴木 恵美子, 片山 紗乙莉, 渡辺 哲, 内田 俊彦, 柏原 俊彦, 今野 昭宏, 饗場 智, 渡辺 眞史, 藤山 純一

    日本小児科学会雑誌　115　(1)　151-151　2011/01

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  77. 母体に投与された硫酸マグネシウムによる早産児の電解質への影響

    片山 紗乙莉, 内田 俊彦, 早川 裕子, 渡辺 哲, 饗場 智, 渡辺 眞史

    日本未熟児新生児学会雑誌　22　(3)　560-560　2010/10

    Publisher: (公社)日本新生児成育医学会

    ISSN： 1347-8540

  78. 重篤な頭蓋内出血で発症した非症候性肝内胆管減少症の1例

    柏原 俊彦, 片山 紗乙莉, 鈴木 恵美子, 渡辺 哲, 内田 俊彦, 今野 昭宏, 饗場 智, 渡辺 真史, 藤山 純一, 熊谷 孝, 林 千代, 虻川 大樹, 武山 淳二

    日本小児科学会雑誌　114　(8)　1244-1244　2010/08

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  79. ヒトヘルペスウイルス7型による突発性発疹関連脳症の1例

    鈴木 恵美子, 片山 紗乙莉, 渡辺 哲, 内田 俊彦, 柏原 俊彦, 今野 昭宏, 饗場 智, 渡辺 真史, 藤山 純一, 加藤 光広, 早坂 清

    日本小児科学会雑誌　114　(8)　1245-1245　2010/08

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  80. 息切れで発症し、貧血、血小板減少、多クローン性高γグロブリン血症を呈した80歳代女性例

    三好 寛明, 本間 りこ, 鴻巣 佐智子, 高橋 利幸, 山内 毅, 荒井 志津葉, 瀬尾 恭一, 青木 倉揚, 湯田 淳一朗, 片山 紗乙莉, 鈴木 有大, 日野 俊彦, 江口 真里子, 鈴木 昌幸, 佐藤 正道, 田村 元, 岡田 宗一郎, 大本 英次郎

    山形県立病院医学雑誌　44　(2)　166-176　2010/07

    Publisher: 山形県病医誌編集委員会

    ISSN： 0389-0848

  81. 維持輸液による高カリウム血症の原因が高マグネシウム血症と考えられた早産児例

    片山 紗乙莉, 内田 奈生, 内田 俊彦, 早川 裕子, 渡辺 哲, 柏原 俊彦, 饗場 智, 渡辺 真史

    日本小児科学会雑誌　114　(2)　283-283　2010/02

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

  82. 発熱と頭痛、関節痛を訴えて救急外来を受診した40歳代後半男性例

    佐々木 真太郎, 三好 寛明, 長谷川 佑介, 佐藤 好宏, 鈴木 有大, 後藤 敏和, 大久保 龍二, 斎藤 裕之, 武田 健一郎, 片山 紗乙莉, 斎藤 彰治, 鈴木 郁子, 江口 真里子, 津久井 秀則, 中村 麻里, 鈴木 昌幸

    山形県立病院医学雑誌　43　(1)　47-57　2009/01

    Publisher: 山形県病医誌編集委員会

    ISSN： 0389-0848

Show all ︎Show first 5

Presentations 8

  1. Genetic analysis of an early T-cell precursor acute lymphoblastic lymphoma associated with myeloproliferative neoplasm

    Saori Katayama, Tomohiro Nakano, Masahiro Irie, Kunihiko Moriya, Hidetaka Niizuma, Takeshi Rikiishi, Yoji Sasahara, Shigeo Kure

  2. 自己免疫症状に対してリツキシマブを使用したWiskott-Aldrich症候群の３例

    片山紗乙莉, 渡辺祐子, 入江正寛, 新妻秀剛, 力石健, 笹原洋二, 呉繁夫

    第122回日本小児科学会学術集会　2019/04/21

  3. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis in an inv(3)(q21q26) mouse model

    Saori Katayama, Mikiko Suzuki, Yoji Sasahara, Shigeo Kure, Masayuki Yamamoto

    第60回日本小児血液・がん学術集会　2018/11/15

  4. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis in an inv(3)(q21q26) mouse model Invited

    片山 紗乙莉

    第14回血液学若手研究者勉強会（麒麟塾）　2018/06/30

  5. GATA2遺伝子ヘテロ欠失は３番染色体逆位を伴う白血病の発症を促進する

    片山紗乙莉, 鈴木未来子, 呉繁夫, 山本雅之

    第89回日本生化学会大会　2016/09/26

  6. GATA2 haploinsufficiency promotes leukemogenesis associated with 3q chromosomal rearrangements.

    Saori Katayama, Mikiko Suzuki, Shigeo Kure, Doug Engel, Masayuki Yamamoto

    20th Hemoglobin Switching Conference　2016/09/15

  7. ３番染色体逆位を伴う急性骨髄性白血病におけるGATA2遺伝子ヘテロ欠失の寄与

    片山紗乙莉, 鈴木未来子, 呉繁夫, 山本雅之

    日本生化学会東北支部第82回例会・シンポジウム　2016/05/22

  8. EVI1遺伝子高発現による白血病発症機構の解明

    片山紗乙莉, 鈴木未来子, 呉繁夫, 山本雅之

    第20回造血器腫瘍研究会　2016/02/12

Show all Show first 5

Research Projects 2

  1. 遺伝性血小板減少症の新規原因遺伝子を介した巨核球・血小板造血メカニズムの解明

    片山 紗乙莉

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業 若手研究

    Category: 若手研究

    Institution: 東北大学

    2022/04/01 - 2025/03/31

  2. Elucidate the importance of MPL in the pathogenesis of hematological diseases caused by abnormal EVI1 expression

    Katayama Saori

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research

    Category: Grant-in-Aid for Early-Career Scientists

    Institution: Tohoku University

    2018/04/01 - 2020/03/31

    More details Close

    Leukemia caused by chromosome 3 inversions/translocations is characterized by thrombocytosis. In this leukemia, overexpression of the EVI1 gene and decreased expression of GATA2 occur. In this study, we investigated the mechanism of thrombocytosis using a mouse model and found that overexpression of EVI1 caused an increase in megakaryocytes and their progenitors even before the onset of leukemia. In addition, the simultaneous reproduction of EVI1 gene overexpression and GATA2 gene downregulation reproduced leukemia with thrombocytosis. This study revealed that the EVI1 and GATA2 genes cooperatively leads to the development of leukemia with thrombocytosis.